Pregabalin

Pre-clinicalTerminated

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Complex Regional Pain Syndromes

Conditions

Complex Regional Pain Syndromes

Trial Timeline

Nov 1, 2007 → Oct 1, 2010

NCT ID

NCT00891397

About Pregabalin

Pregabalin is a pre-clinical stage product being developed by Pfizer for Complex Regional Pain Syndromes. The current trial status is terminated. This product is registered under clinical trial identifier NCT00891397. Target conditions include Complex Regional Pain Syndromes.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01773993	Pre-clinical	Completed	Feb 1, 2013	Jul 1, 2017	Pain Associated With Fibromyalgia
NCT01603394	Approved	Terminated	Oct 1, 2012	Jun 1, 2013	Postherpetic Neuralgia
NCT01463306	Phase 3	Completed	Feb 21, 2012	Aug 22, 2019	Epilepsy, Partial Seizures
NCT01298466	Approved	Withdrawn	Feb 1, 2012	Feb 1, 2013	Low Back Pain
NCT01474772	Phase 3	Completed	Oct 1, 2011	Jul 1, 2013	Diabetic Peripheral Neuropathy
NCT01397006	Approved	Withdrawn	Sep 1, 2011	Mar 1, 2014	Fibromyalgia
NCT01020526	Approved	Completed	Sep 1, 2010	Jun 1, 2015	Fibromyalgia
NCT01202227	Phase 3	Completed	Sep 1, 2010	Mar 1, 2012	Spinal Cord Diseases
NCT01226667	Approved	Completed	Jul 1, 2010	Jul 1, 2012	Fibromyalgia
NCT00819988	Phase 3	Completed	May 1, 2009	Oct 1, 2011	Delirium
NCT00596466	Phase 3	Completed	Apr 1, 2008	Dec 1, 2011	Epilepsy
NCT00553280	Phase 3	Completed	Feb 1, 2008	Jan 1, 2010	Diabetic Neuropathy, Painful
NCT01061697	Approved	Completed	Jan 1, 2008	Apr 1, 2010	Cervical Spondylosis
NCT00891397	Pre-clinical	Terminated	Nov 1, 2007	Oct 1, 2010	Complex Regional Pain Syndromes
NCT00448916	Phase 3	Completed	May 1, 2007	Oct 1, 2013	Epilepsies, Partial
NCT00407797	Approved	Terminated	Mar 1, 2007	Aug 1, 2009	Partial Seizures
NCT00424372	Phase 3	Completed	Jan 12, 2007	Aug 19, 2008	Neuralgia, Postherpetic
NCT00407511	Approved	Completed	Jan 1, 2007	Jul 1, 2008	Diabetic Peripheral Neuropathic Pain (DPN)
NCT00346034	Phase 3	Completed	Dec 1, 2006	Feb 1, 2008	Fibromyalgia
NCT00843284	Pre-clinical	Completed	Sep 1, 2006	Mar 1, 2008	Neuropathic Pain

Competing Products

20 competing products in Complex Regional Pain Syndromes

See all competitors

Product	Company	Stage	Hype Score
Zonisamide	Eisai	Phase 3	77
Eslicarbazepine acetate + Eslicarbazepine acetate	Sumitomo Pharma	Phase 3	77
Everolimus (RAD001) + Everolimus Placebo	Novartis	Phase 3	77
Zoledronic acid + Placebo	Novartis	Phase 2	52
RAD001 + Placebo	Novartis	Phase 2	52
RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase)	Novartis	Phase 3	77
everolimus	Novartis	Phase 3	77
ranolazine	Gilead Sciences	Phase 2	51
clarithromycin, rifabutin	Pfizer	Approved	84
Pregabalin + Pregabalin	Pfizer	Approved	84
Azithromycin	Pfizer	Approved	84
Azithromycin + Rifabutin/rifampin	Pfizer	Approved	84
Stavudine	Bristol Myers Squibb	Phase 3	76
Zidovudine + Didanosine	Bristol Myers Squibb	Phase 2	51
Haemocomplettan® P + Human albumin (Placebo)	CSL	Phase 2/3	64
BE1116 + FFP	CSL	Phase 3	76
CSL730 + Placebo	CSL	Phase 1	32
vigabatrin	Lundbeck	Approved	82
Sabril	Lundbeck	Approved	82
GWP42003-P	Jazz Pharmaceuticals	Phase 3	74

Other Products from Pfizer